BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wu HX, Ding XY, Xu YW, Yu MH, Li XM, Deng N, Chen JL. Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus. World J Gastroenterol 2024; 30(8): 843-854 [PMID: 38516240 DOI: 10.3748/wjg.v30.i8.843]
URL: https://www.wjgnet.com/1007-9327/full/v30/i8/843.htm
Number Citing Articles
1
Daniele Ferraro, Federica Falaschi, Luca Nazzaro, Giovanni Vennarecci. Impact of neoadjuvant multimodal therapy in the setting of locally advanced hepatocellular carcinomaWorld Journal of Gastroenterology 2024; 30(28): 3452-3455 doi: 10.3748/wjg.v30.i28.3452
2
Yuhang Chen, Suoyi Dai, Chien-shan Cheng, Lianyu Chen. Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectivesJournal of Hematology & Oncology 2024; 17(1) doi: 10.1186/s13045-024-01647-1
3
Changjie Du, Hongyu Wu, Tao Zhong, Qilong Zhai, Jiajun Yuan, Jialun Peng, Rong Ma, Jinzheng Li. Interventional therapy combined with tyrosine kinase inhibitors with or without immune checkpoint inhibitors as initial treatment for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysisDiscover Oncology 2024; 15(1) doi: 10.1007/s12672-024-01026-9
4
Yue Chen, Luyao Jia, Yu Li, Wenhao Cui, Jukun Wang, Chao Zhang, Chunjing Bian, Tao Luo. Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysisFrontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1466113